Still haven't had a chance to listen to the call(but expect it to be an encouraging experience when I do).
If Hs equal enthusiasm for EGFR is warranted(poor choice of words), short of ALK being a disappointment(highly unlikely), more positive surprises should be in the offing.
Personally, I wonder about how much of erlotinib's effectiveness is, despite the attendant side effects, due to it's role in inhibiting native EGFR-
To the degree that it is, 113s (single drug)EGFR performance, though involving less side effects, may be less efficacious than hoped for.
Are you aware of any updated data relating to this issue?
Re: Pona-Well, it just seems to be continuously onward and upward, and we haven't even seen any data(which should be forthcoming) on other tumor types!